229 / 1109
German Cancer Consortium (DKTK)
LUNGTECH – KEY NOTES
Study treatment:
- SBRT of centrally located NSCLC (T1-T3 N0)
- 8 X 7.5 Gy, GD 60Gy, ICRU 83
Primary endpoint:
to evaluate the freedom of local progression rate
at 3 years
Secondary endpoints:
−
acute and late toxicity (stopping rules)
−
pattern of local and distant recurrence
−
overall survival and causes of death
Sites:
−
23 Participating sites have been selected from 7 European countries
Timmerman et al , JCO 2006